Biogen's difficult launch of controversial Alzheimer's therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain patients enrolled in clinical t
Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.
Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer's programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up t
The Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai's Alzheimer's disease therapy Aduhelm, leaving the FDA an outlier in its st
Biogen has cut the list price of its Alzheimer's disease therapy in half from $56,000 to $28,200 a year, before the outcome of an ongoing reimbursement review of the drug by the US governme